Max HealthcareQ2 FY24

Max Healthcare Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,030.9P/E: 70.6Market Cap: ₹1.0L CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • Occupied bed days grew 3% YoY and 5% QoQ with average occupancy at 77%; inpatient discharges up 7% YoY.
  • Network gross revenue increased 17% YoY, driven by ARPOB growth and higher occupied bed days.
  • Revenue from international business grew 25% YoY and 11% QoQ; international revenue now ~9% of hospital revenue.
  • Oncology specialty revenue growing faster (26%-28%) than overall business (17%), driven by higher disease burden and insurance penetration.
  • Capacity to expand with 2,600 beds coming online over next 3-4 years, adding significant growth runway.
  • Institutional business ARPOB up 28% YoY due to mix change rather than price hike.
  • Expect continued multi-decade growth opportunity due to under-penetration of quality healthcare in India.
  • EBITDA and cash flow expected to maintain robust growth trajectory with bed expansions and operational efficiencies.

See what Max Healthcare management said on margin guidance — free account, 30 seconds.

Fundraise plans

- The management did not mention any immediate plans for fundraising through debt or equity during the call. - They highlighted accumulating cash and being conscious of fiscal discipline in deployments. - Cash and leverage capacity are viewed as limited relative to large acquisition opportunities available at high valuations (15-16X EV/EBITDA). - They intend to deploy capital carefully, balancing expansion and acquisitions with fiscal prudence. - No explicit mention of upcoming debt or equity issuance was made; instead, focus is on organic growth, brownfield expansions, and select acquisitions. - The existing cash and balance sheet strength are considered adequate for near-term expansion, with plans to announce acquisitions soon. Overall, no current or immediate new fundraising through debt or equity was disclosed.

See what Max Healthcare management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Ongoing expansions include 2,600 beds with 300 beds expected by FY24-end and approximately 819 beds in FY25 (Nanavati 329 beds, Mohali 190 beds, Gurgaon 300 beds).
  • Max Shalimar Bagh brownfield expansion operational with 78% occupancy; brownfields have quick EBITDA breakeven (within quarter or two).
  • Greenfield projects comprise 10% of expansion with breakeven expected within 12 months.
  • Max Smart at Saket: 350 beds delayed but work to restart by Dec 2023.
  • Max Vikrant at Saket and Patparganj expansions progressing with approvals underway.
  • Strategic focus on fiscal discipline while deploying cash; acquisitions considered at right price but prefer built-to-suit, asset-light models over Greenfields.
  • Developer of Dwarka hospital (300 beds) applied for occupancy certificate, expected commissioning Q4 2023.
  • Planned capital deployment on both capacity expansion and inorganic opportunities; accumulation of cash with intent to invest soon.

Track Max Healthcare — get its next earnings analysis in your feed

How does Max Healthcare rank vs peers in Healthcare Services?

Pro feature
ThisMax Healthcare
Rev 2Mar 3

How does Max Healthcare rank in Healthcare Services?

Compare Max Healthcare against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →